Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Context Therapeutics Inc (NQ: CNTX )

0.6200 +0.0101 (+1.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 49,837
Open 0.6000
Bid (Size) 0.5682 (13)
Ask (Size) 0.6200 (19)
Prev. Close 0.6099
Today's Range 0.5801 - 0.6320
52wk Range 0.5600 - 2.790
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2023
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga

Performance

YTD
-8.03%
-8.03%
1 Month
-19.50%
-19.50%
3 Month
-6.63%
-6.63%
6 Month
-48.33%
-48.33%
1 Year
-70.48%
-70.48%

More News

Read More
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
From Context Therapeutics Inc.
Via Globe NewsWire
Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
From Context Therapeutics Inc.
Via Globe NewsWire
$7M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Buying
Via Benzinga
Context Therapeutics And 3 Other Stocks Under $2 Insiders Are Aggressively Buying
Via Benzinga
Insiders Buying AmeriServ Financial And 2 Other Penny Stocks
Via Benzinga
Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
From Context Therapeutics Inc.
Via Globe NewsWire
Why TransCode Therapeutics Shares Are Trading Higher By 42%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Tesla, Amazon, Apple, Context Therapeutics, Snap: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
Dow Surges Over 200 Points; Pfizer Issues Weak Forecast
Via Benzinga
Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Context Therapeutics (CNTX) Shares Are Seeing Blue Skies
Via Benzinga
Dow Turns Higher; Nasdaq Jumps 100 Points
Via Benzinga
Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
From Context Therapeutics Inc.
Via Globe NewsWire
$1 Million Bet On Motorsport Games? Check Out These 4 Penny Stocks Insiders Are Buying
Via Benzinga
Context Therapeutics And 3 Other Stocks Under $1 Insiders Are Aggressively Buying
Via Benzinga
Myomo, Enzo Biochem And These 2 Stocks Under $2 Insiders Are Aggressively Buying
Via Benzinga
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
From Context Therapeutics Inc.
Via Globe NewsWire
Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones
From Context Therapeutics Inc.
Via Globe NewsWire
Why Context Therapeutics Stock Is Falling 25% Today
Via Benzinga
Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
From Context Therapeutics Inc.
Via Globe NewsWire
Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
From Context Therapeutics Inc.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.